Windlas Biotech Limited

BSE: 543329 NSE: WINDLAS
Windlas Biotech Limited - pharma in Dehradun, Uttarakhand, India. FY 2026 financials and compliance.
CIN L74899UR2001PLC033407 Incorporated 19 February 2001 ROC Uttarakhand HQ Dehradun, Uttarakhand, India
Active Listed - NSE: WINDLAS · BSE: 543329 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹904.09 Cr
▲ 18.98% YoY
EBITDA · FY 2026
₹122.55 Cr
▲ 9.29% YoY
Net profit · FY 2026
₹66.46 Cr
▲ 8.95% YoY
Authorised capital
₹77.5 Cr
Registered with MCA
Paid-up capital
₹10.54 Cr
Issued & subscribed
Open charges
₹73.3 Cr
Satisfied ₹183.4 Cr
Company age
25 yrs
Est. 2001
Employees · EPFO
1,153
Latest available

About Windlas Biotech Limited

Data last updated: 18 February 2026

Windlas Biotech Limited is a public limited company based in Dehradun, Uttarakhand, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 19 February 2001, the company has been in operation for over 25 years.

Registered with ROC Uttarakhand under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS.

Capital: an authorised share capital of ₹77.5 Cr and a paid-up capital of ₹10.54 Cr. Formerly known as Windlas Biotech Private Limited. It is led by directors including Hitesh Windlass and Pawan Kumar Sharma.

Last AGM: 28 July 2025. Financial statements filed for year ended 31 March 2025. Office: 40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110.

As per the financials filed for FY 2025, the company reported a revenue of ₹777.9 Cr, a growth of 21% compared to the previous year.

The company has a workforce of approximately 1,153 employees as per the latest available data.

The company is associated with 1 brand - Windlas. As per MCA filings, the company has open charges of ₹73.3 Cr and satisfied charges of ₹183.4 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website windlas.com.

Company Details of Windlas Biotech Limited
CIN L74899UR2001PLC033407
Registration Number 033407
Incorporation Date 19 February 2001
ROC Uttarakhand
Listing Status Listed (BSE: 543329, NSE: WINDLAS)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Hitesh Windlass Managing Director Pawan Kumar Sharma Whole-Time Director Ashok Kumar Windlass Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    windlas.com
  • Social Media
  • Registered Address
    40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110
  • Industry
    Pharma, Drug Formulation & Development
Company report
Windlas Biotech Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Windlas Biotech Limited report

Financials, compliance, directors, charges, ownership and filings for Windlas Biotech Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Windlas Biotech Limited

Windlas Biotech Limited has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899UR2001PLC033407, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74899UR2001PLC033407 Current
U74899UR2001PLC033407 Previous
U74899DL2001PLC109721 Previous
U74899UR2001PTC033407 Previous

Associated Brands with Windlas Biotech Limited

Windlas Biotech Limited operates one associated brand: Windlas. These brands represent Windlas Biotech Limited's diversified market presence and brand portfolio.

Brand Description Website
Windlas
Biopharma regulatory affairs, quality control, and strategy services are provided. windlas.com

Competitors & Alternatives of Windlas Biotech Limited

Brands and companies operating in the same space as Windlas Biotech Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 4 more.

Competitor Description Location Founded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and generics Noida, India, India 1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995
CoreRx CoreRx CDMO with a focus on early phase drug product development Clearwater, United States, United States 2006
MedPharm MedPharm Topical and inhaled drug delivery formulations are developed and manufactured. Guildford, United Kingdom, United Kingdom 1998

Business Activity of Windlas Biotech Limited

Windlas Biotech Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Windlas Biotech Limited

Windlas Biotech Limited is audited by SS KOTHARI METHA & COMPANY LLP for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
SS KOTHARI METHA & COMPANY LLP blur-value blur-value blur-value

Board of Directors of Windlas Biotech Limited

Windlas Biotech Limited is currently managed by 10 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Hitesh Windlass
Also directs: Windlas Biotech Limited
Managing Director 21 Jan 2008 18 Years 5 Months Current
Pawan Kumar Sharma
Also directs: Windlas Biotech Limited
Whole-Time Director 11 Jun 2019 7 Years 0 Months Current
Manoj Kumar Windlass
Also directs: Windlas Biotech Limited, Windlas Exports Private Limited
Person Incharge 17 Jul 2015 10 Years 11 Months Current
Prachi Jain Windlass
Also directs: Windlas Biotech Limited, Michael & Susan Dell Foundation India Llp
Director 03 May 2021 5 Years 2 Months Current
Gaurav Gulati
Also directs: Windlas Biotech Limited, Aroa Innovation Partners Llp, Redsprig Innovation Partners Llp and 5 more
Director 06 May 2021 5 Years 2 Months Current
Srinivasan Venkataraman
Also directs: Windlas Biotech Limited, Ivrcl Chengapalli Tollways Limited, Practus Advisors Private Limited and 4 more
Director 06 May 2021 5 Years 2 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Windlas Biotech Limited FY 2026 filings available

Windlas Biotech Limited reported revenue of ₹904.09 Cr (up 18.98% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹904.09 Cr ▲ 18.98%
Profit · FY 2026
₹66.46 Cr ▲ 8.95%
EBITDA · FY 2026
₹122.55 Cr ▲ 9.29%
Revenue₹ Cr · Consolidated05001,000FY 2022: ₹466 Cr466FY 2022FY 2023: ₹513 Cr · +10.1% YoY513+10.1%FY 2023FY 2024: ₹631 Cr · +23% YoY631+23%FY 2024FY 2025: ₹760 Cr · +20.4% YoY760+20.4%FY 2025FY 2026: ₹904 Cr · +19% YoY904+19%FY 2026
Net Profit₹ Cr · Consolidated0255075FY 2022: ₹38 Cr38.1FY 2022FY 2023: ₹43 Cr · +11.9% YoY42.6+11.9%FY 2023FY 2024: ₹58 Cr · +36.5% YoY58.2+36.5%FY 2024FY 2025: ₹61 Cr · +4.8% YoY61+4.8%FY 2025FY 2026: ₹66 Cr · +9% YoY66.5+9%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0100200300Q1'25: ₹175 Cr · +21% YoY175+21%Q1'25Q2'25: ₹187 Cr · +22.5% YoY187+22.5%Q2'25Q3'25: ₹195 Cr · +20.2% YoY195+20.2%Q3'25Q4'25: ₹203 Cr · +18.3% YoY203+18.3%Q4'25Q1'26: ₹210 Cr · +19.9% YoY210+19.9%Q1'26Q2'26: ₹222 Cr · +18.9% YoY222+18.9%Q2'26Q3'26: ₹233 Cr · +19.5% YoY233+19.5%Q3'26Q4'26: ₹238 Cr · +17.7% YoY238+17.7%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Revenue from Operations ₹904.09 Cr ₹759.88 Cr ₹630.96 Cr ₹513.08 Cr ₹465.93 Cr
Other Income ₹17.8 Cr ₹18.02 Cr ₹13.47 Cr ₹9.97 Cr ₹6.71 Cr
Total Income ₹921.89 Cr ₹777.9 Cr ₹644.42 Cr ₹523.05 Cr ₹472.64 Cr
Cost of Materials Consumed ₹12.46 Cr ₹2.33 Cr ₹2.96 Cr -₹76.2 Lakh ₹307.56 Cr
Purchases of Stock-in-Trade ₹537.67 Cr ₹491.05 Cr ₹383.63 Cr ₹341.48 Cr ₹0
Changes in Inventories ₹7.1 Cr -₹21.52 Cr ₹9.59 Cr -₹15.27 Cr -₹4.74 Cr
Employee Benefit Expense ₹152.09 Cr ₹122.92 Cr ₹87.46 Cr ₹70.32 Cr ₹63.41 Cr
Finance Costs ₹4.83 Cr ₹4.38 Cr ₹1.11 Cr ₹78.8 Lakh ₹1.42 Cr
Depreciation & Amortisation ₹30.74 Cr ₹27.99 Cr ₹13.44 Cr ₹12.36 Cr ₹12.15 Cr
Other Expenses ₹90.02 Cr ₹71 Cr ₹69.15 Cr ₹57.09 Cr ₹47.28 Cr
Total Expenses ₹834.92 Cr ₹698.14 Cr ₹567.33 Cr ₹466.01 Cr ₹427.07 Cr
Profit Before Exceptional Items & Tax ₹86.98 Cr ₹79.76 Cr ₹77.09 Cr ₹57.04 Cr ₹45.57 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹86.98 Cr ₹79.76 Cr ₹77.09 Cr ₹57.04 Cr ₹45.57 Cr
Total Tax Expense ₹20.52 Cr ₹18.76 Cr ₹18.9 Cr ₹14.41 Cr ₹7.48 Cr
Net Profit ₹66.46 Cr ₹60.99 Cr ₹58.19 Cr ₹42.63 Cr ₹38.09 Cr
  attributable to Owners - ₹0 ₹0 - ₹37.9 Cr
  attributable to NCI - ₹0 ₹0 - ₹0
Other Comprehensive Income ₹11.1 Lakh -₹54.9 Lakh -₹24.8 Lakh -₹18.3 Lakh -₹18.6 Lakh
Total Comprehensive Income ₹66.57 Cr ₹60.45 Cr ₹57.94 Cr ₹42.44 Cr ₹37.9 Cr
EBITDA (computed) ₹122.55 Cr ₹112.13 Cr ₹91.64 Cr ₹70.19 Cr ₹59.13 Cr
Basic EPS ₹31.60 ₹29.19 ₹27.97 ₹19.70 ₹18.80
Diluted EPS ₹31.15 ₹28.87 ₹27.88 ₹19.70 ₹18.80
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹907.35 Cr ₹760.45 Cr ₹626.21 Cr ₹528.98 Cr
Non-current Assets ₹280.5 Cr ₹235.32 Cr ₹194.92 Cr ₹175.44 Cr
Current Assets ₹626.85 Cr ₹525.13 Cr ₹431.29 Cr ₹353.54 Cr
Property, Plant & Equipment ₹187.18 Cr ₹195.49 Cr ₹169.49 Cr ₹102.6 Cr
Inventories ₹61.82 Cr ₹81.38 Cr ₹62.19 Cr ₹74.74 Cr
Trade Receivables ₹227.4 Cr ₹166.86 Cr ₹136.28 Cr ₹116.86 Cr
Cash & Equivalents ₹53.5 Lakh ₹42.4 Lakh ₹5.29 Cr ₹3.69 Cr
Equity (Net Worth) ₹580.84 Cr ₹505.77 Cr ₹449.94 Cr ₹402.27 Cr
Equity Share Capital ₹10.55 Cr ₹10.48 Cr ₹10.4 Cr ₹10.46 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹10.9 Lakh
Borrowings (Current) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹33.5 Lakh
Total Debt (computed) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹44.4 Lakh
Current Liabilities ₹320.93 Cr ₹249.44 Cr ₹171.75 Cr ₹121.24 Cr
Total Liabilities ₹326.51 Cr ₹254.68 Cr ₹176.27 Cr ₹126.7 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹104.93 Cr ₹68.19 Cr ₹108.96 Cr ₹60.97 Cr ₹9.13 Cr
Investing Cash Flow -₹91.79 Cr -₹74.06 Cr -₹92.07 Cr -₹14.11 Cr -₹154.58 Cr
Financing Cash Flow -₹13.03 Cr ₹1.01 Cr -₹15.29 Cr -₹43.74 Cr ₹130.09 Cr
Capital Expenditure ₹67.66 Cr ₹52.19 Cr ₹37.68 Cr ₹70.89 Cr ₹14.8 Cr
Free Cash Flow (computed) ₹37.27 Cr ₹15.99 Cr ₹71.28 Cr -₹9.93 Cr -₹5.67 Cr
Dividends Paid ₹12.16 Cr ₹11.5 Cr ₹8.3 Cr ₹7.63 Cr ₹0
Net Change in Cash ₹11.1 Lakh -₹4.86 Cr ₹1.6 Cr ₹3.12 Cr -₹15.36 Cr
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹238.5 Cr ₹233.1 Cr ₹222.4 Cr ₹210.09 Cr ₹202.71 Cr ₹195.02 Cr ₹187 Cr ₹175.15 Cr ₹171.29 Cr ₹162.21 Cr ₹152.67 Cr ₹144.79 Cr
Other Income ₹4.35 Cr ₹4.57 Cr ₹3.65 Cr ₹5.24 Cr ₹4.94 Cr ₹4.11 Cr ₹4.84 Cr ₹4.13 Cr ₹4.44 Cr ₹3.16 Cr ₹3.24 Cr ₹2.62 Cr
Total Income ₹242.85 Cr ₹237.67 Cr ₹226.04 Cr ₹215.33 Cr ₹207.64 Cr ₹199.13 Cr ₹191.84 Cr ₹179.29 Cr ₹175.73 Cr ₹165.38 Cr ₹155.91 Cr ₹147.41 Cr
Cost of Materials Consumed ₹3.78 Cr -₹5.47 Cr ₹8.04 Cr ₹6.11 Cr ₹3.33 Cr ₹87.7 Lakh ₹37.7 Lakh -₹2.26 Cr ₹2.06 Cr -₹5.43 Cr ₹4.35 Cr ₹1.98 Cr
Purchases of Stock-in-Trade ₹141.68 Cr ₹140.4 Cr ₹136.25 Cr ₹119.35 Cr ₹111.77 Cr ₹133.64 Cr ₹127.17 Cr ₹118.48 Cr ₹104.55 Cr ₹105.34 Cr ₹86.45 Cr ₹87.29 Cr
Changes in Inventories ₹1.59 Cr ₹8.58 Cr -₹7.34 Cr ₹4.28 Cr ₹10.1 Cr -₹13.68 Cr -₹11.12 Cr -₹6.82 Cr ₹54.7 Lakh ₹1.73 Cr ₹5.08 Cr ₹2.24 Cr
Employee Benefit Expense ₹41.37 Cr ₹42.05 Cr ₹36.45 Cr ₹32.23 Cr ₹31.93 Cr ₹32.17 Cr ₹30.97 Cr ₹27.85 Cr ₹22.85 Cr ₹22.73 Cr ₹21.32 Cr ₹20.56 Cr
Finance Costs ₹1.48 Cr ₹1.28 Cr ₹1.02 Cr ₹1.06 Cr ₹1.33 Cr ₹1.46 Cr ₹1.1 Cr ₹49.2 Lakh ₹27.7 Lakh ₹30.5 Lakh ₹28.5 Lakh ₹23.8 Lakh
Depreciation & Amortisation ₹8 Cr ₹7.7 Cr ₹7.6 Cr ₹7.45 Cr ₹8.34 Cr ₹6.94 Cr ₹6.5 Cr ₹6.21 Cr ₹3.54 Cr ₹3.39 Cr ₹3.33 Cr ₹3.19 Cr
Other Expenses ₹24.79 Cr ₹23.18 Cr ₹20.45 Cr ₹21.61 Cr ₹20.04 Cr ₹17.39 Cr ₹16.56 Cr ₹17.02 Cr ₹19.28 Cr ₹17.5 Cr ₹16.8 Cr ₹15.58 Cr
Total Expenses ₹222.69 Cr ₹217.7 Cr ₹202.46 Cr ₹192.07 Cr ₹186.82 Cr ₹178.79 Cr ₹171.56 Cr ₹160.98 Cr ₹153.09 Cr ₹145.57 Cr ₹137.6 Cr ₹131.07 Cr
Profit Before Exceptional Items & Tax ₹20.16 Cr ₹19.97 Cr ₹23.59 Cr ₹23.26 Cr ₹20.82 Cr ₹20.34 Cr ₹20.29 Cr ₹18.31 Cr ₹22.63 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹20.16 Cr ₹19.97 Cr ₹23.59 Cr ₹23.26 Cr ₹20.82 Cr ₹20.34 Cr ₹20.29 Cr ₹18.31 Cr ₹22.63 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Total Tax Expense ₹4.17 Cr ₹4.97 Cr ₹5.79 Cr ₹5.59 Cr ₹4.54 Cr ₹4.76 Cr ₹4.63 Cr ₹4.83 Cr ₹5.64 Cr ₹4.71 Cr ₹4.28 Cr ₹4.28 Cr
Net Profit ₹15.99 Cr ₹15 Cr ₹17.8 Cr ₹17.66 Cr ₹16.28 Cr ₹15.58 Cr ₹15.66 Cr ₹13.48 Cr ₹16.99 Cr ₹15.1 Cr ₹14.03 Cr ₹12.07 Cr
  attributable to Owners - ₹0 - ₹0 ₹0 ₹0 ₹0 - ₹0 ₹15.1 Cr - -
  attributable to NCI - ₹0 - ₹0 ₹0 ₹0 ₹0 - ₹0 ₹0 - -
Other Comprehensive Income ₹7.9 Lakh ₹17.3 Lakh -₹17.6 Lakh ₹3.6 Lakh ₹15.9 Lakh -₹2.1 Lakh -₹22.3 Lakh -₹46.4 Lakh ₹3.5 Lakh ₹2.6 Lakh ₹1.9 Lakh -₹32.8 Lakh
Total Comprehensive Income ₹16.07 Cr ₹15.18 Cr ₹17.62 Cr ₹17.7 Cr ₹16.44 Cr ₹15.56 Cr ₹15.44 Cr ₹13.02 Cr ₹17.03 Cr ₹15.12 Cr ₹14.05 Cr ₹11.74 Cr
EBITDA (computed) ₹29.64 Cr ₹28.95 Cr ₹32.2 Cr ₹31.76 Cr ₹30.49 Cr ₹28.74 Cr ₹27.89 Cr ₹25.01 Cr ₹26.45 Cr ₹23.5 Cr ₹21.93 Cr ₹19.77 Cr
Basic EPS ₹7.58 ₹7.12 ₹8.48 ₹8.43 ₹7.77 ₹7.45 ₹7.49 ₹6.47 ₹8.17 ₹7.26 ₹6.75 ₹5.79
Diluted EPS ₹7.49 ₹7.05 ₹8.40 ₹8.34 ₹7.69 ₹7.38 ₹7.43 ₹6.44 ₹8.14 ₹7.26 ₹6.75 ₹5.79
Latest 12 quarters shown of 20 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Revenue from Operations ₹904.09 Cr ₹759.88 Cr ₹630.96 Cr ₹513.08 Cr ₹465.93 Cr
Other Income ₹17.8 Cr ₹17.65 Cr ₹13.47 Cr ₹9.97 Cr ₹6.71 Cr
Total Income ₹921.89 Cr ₹777.52 Cr ₹644.42 Cr ₹523.05 Cr ₹472.64 Cr
Cost of Materials Consumed ₹12.46 Cr ₹2.33 Cr ₹2.96 Cr -₹76.2 Lakh ₹307.56 Cr
Purchases of Stock-in-Trade ₹537.67 Cr ₹491.05 Cr ₹383.63 Cr ₹341.48 Cr ₹0
Changes in Inventories ₹7.1 Cr -₹21.52 Cr ₹9.59 Cr -₹15.27 Cr -₹4.74 Cr
Employee Benefit Expense ₹152.09 Cr ₹122.92 Cr ₹87.46 Cr ₹70.32 Cr ₹63.41 Cr
Finance Costs ₹4.83 Cr ₹4.38 Cr ₹1.1 Cr ₹78.6 Lakh ₹1.42 Cr
Depreciation & Amortisation ₹30.74 Cr ₹27.99 Cr ₹13.44 Cr ₹12.36 Cr ₹12.15 Cr
Other Expenses ₹90.07 Cr ₹70.99 Cr ₹69.22 Cr ₹57.07 Cr ₹46.81 Cr
Total Expenses ₹834.96 Cr ₹698.13 Cr ₹567.4 Cr ₹465.99 Cr ₹426.6 Cr
Profit Before Exceptional Items & Tax ₹86.93 Cr ₹79.39 Cr ₹77.02 Cr ₹57.06 Cr ₹46.04 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹86.93 Cr ₹79.39 Cr ₹77.02 Cr ₹57.06 Cr ₹46.04 Cr
Total Tax Expense ₹20.5 Cr ₹18.75 Cr ₹18.88 Cr ₹14.41 Cr ₹7.48 Cr
Net Profit ₹66.44 Cr ₹60.65 Cr ₹58.14 Cr ₹42.64 Cr ₹38.56 Cr
Other Comprehensive Income ₹11.1 Lakh -₹54.3 Lakh -₹24.3 Lakh -₹15.6 Lakh -₹18 Lakh
Total Comprehensive Income ₹66.55 Cr ₹60.11 Cr ₹57.9 Cr ₹42.49 Cr ₹38.38 Cr
EBITDA (computed) ₹122.5 Cr ₹111.76 Cr ₹91.57 Cr ₹70.21 Cr ₹59.6 Cr
Basic EPS ₹31.59 ₹29.03 ₹27.95 ₹19.71 ₹18.81
Diluted EPS ₹31.14 ₹28.71 ₹27.86 ₹19.71 ₹18.81
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹907.34 Cr ₹760.45 Cr ₹626.16 Cr ₹529.01 Cr
Non-current Assets ₹280.5 Cr ₹235.32 Cr ₹194.92 Cr ₹175.47 Cr
Current Assets ₹626.84 Cr ₹525.13 Cr ₹431.24 Cr ₹353.54 Cr
Property, Plant & Equipment ₹187.18 Cr ₹195.49 Cr ₹169.49 Cr ₹102.6 Cr
Inventories ₹61.82 Cr ₹81.38 Cr ₹62.19 Cr ₹74.74 Cr
Trade Receivables ₹227.4 Cr ₹166.86 Cr ₹136.28 Cr ₹116.86 Cr
Cash & Equivalents ₹52.6 Lakh ₹42.1 Lakh ₹5.24 Cr ₹3.69 Cr
Equity (Net Worth) ₹580.83 Cr ₹505.79 Cr ₹450.29 Cr ₹402.67 Cr
Equity Share Capital ₹10.55 Cr ₹10.48 Cr ₹10.4 Cr ₹10.46 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹10.9 Lakh
Borrowings (Current) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹33.5 Lakh
Total Debt (computed) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹44.4 Lakh
Current Liabilities ₹320.93 Cr ₹249.42 Cr ₹171.35 Cr ₹120.88 Cr
Total Liabilities ₹326.51 Cr ₹254.66 Cr ₹175.87 Cr ₹126.34 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹104.93 Cr ₹68.23 Cr ₹108.91 Cr ₹60.98 Cr ₹9 Cr
Investing Cash Flow -₹91.79 Cr -₹74.06 Cr -₹92.07 Cr -₹14.11 Cr -₹154.31 Cr
Financing Cash Flow -₹13.03 Cr ₹1.01 Cr -₹15.29 Cr -₹43.74 Cr ₹130.09 Cr
Capital Expenditure ₹67.66 Cr ₹52.19 Cr ₹37.68 Cr ₹70.89 Cr ₹14.8 Cr
Free Cash Flow (computed) ₹37.26 Cr ₹16.04 Cr ₹71.23 Cr -₹9.91 Cr -₹5.8 Cr
Dividends Paid ₹12.16 Cr ₹11.5 Cr ₹8.3 Cr ₹7.63 Cr ₹0
Net Change in Cash ₹10.5 Lakh -₹4.82 Cr ₹1.56 Cr ₹3.13 Cr -₹15.22 Cr
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹238.5 Cr ₹233.1 Cr ₹222.4 Cr ₹210.09 Cr ₹202.71 Cr ₹195.02 Cr ₹187 Cr ₹175.15 Cr ₹171.29 Cr ₹162.21 Cr ₹152.67 Cr ₹144.79 Cr
Other Income ₹4.4 Cr ₹4.52 Cr ₹3.65 Cr ₹5.24 Cr ₹4.94 Cr ₹3.73 Cr ₹4.84 Cr ₹4.13 Cr ₹4.44 Cr ₹3.16 Cr ₹3.24 Cr ₹2.62 Cr
Total Income ₹242.9 Cr ₹237.62 Cr ₹226.04 Cr ₹215.33 Cr ₹207.65 Cr ₹198.75 Cr ₹191.84 Cr ₹179.29 Cr ₹175.73 Cr ₹165.38 Cr ₹155.91 Cr ₹147.41 Cr
Cost of Materials Consumed ₹3.78 Cr -₹5.47 Cr ₹8.04 Cr ₹6.11 Cr ₹3.33 Cr ₹87.7 Lakh ₹37.7 Lakh -₹2.26 Cr ₹2.06 Cr -₹5.43 Cr ₹4.35 Cr ₹1.98 Cr
Purchases of Stock-in-Trade ₹141.68 Cr ₹140.4 Cr ₹136.25 Cr ₹119.35 Cr ₹111.77 Cr ₹133.64 Cr ₹127.17 Cr ₹118.48 Cr ₹104.55 Cr ₹105.34 Cr ₹86.45 Cr ₹87.29 Cr
Changes in Inventories ₹1.59 Cr ₹8.58 Cr -₹7.34 Cr ₹4.28 Cr ₹10.1 Cr -₹13.68 Cr -₹11.12 Cr -₹6.82 Cr ₹54.7 Lakh ₹1.73 Cr ₹5.08 Cr ₹2.24 Cr
Employee Benefit Expense ₹41.37 Cr ₹42.05 Cr ₹36.45 Cr ₹32.23 Cr ₹31.93 Cr ₹32.17 Cr ₹30.97 Cr ₹27.85 Cr ₹22.85 Cr ₹22.73 Cr ₹21.32 Cr ₹20.56 Cr
Finance Costs ₹1.48 Cr ₹1.28 Cr ₹1.02 Cr ₹1.06 Cr ₹1.33 Cr ₹1.46 Cr ₹1.1 Cr ₹49.2 Lakh ₹27.6 Lakh ₹30.5 Lakh ₹28.5 Lakh ₹23.7 Lakh
Depreciation & Amortisation ₹8 Cr ₹7.7 Cr ₹7.6 Cr ₹7.45 Cr ₹8.34 Cr ₹6.94 Cr ₹6.5 Cr ₹6.21 Cr ₹3.54 Cr ₹3.39 Cr ₹3.33 Cr ₹3.19 Cr
Other Expenses ₹24.84 Cr ₹23.18 Cr ₹20.45 Cr ₹21.61 Cr ₹20.04 Cr ₹17.38 Cr ₹16.56 Cr ₹17.02 Cr ₹19.35 Cr ₹17.5 Cr ₹16.8 Cr ₹15.58 Cr
Total Expenses ₹222.74 Cr ₹217.7 Cr ₹202.46 Cr ₹192.07 Cr ₹186.82 Cr ₹178.78 Cr ₹171.56 Cr ₹160.98 Cr ₹153.16 Cr ₹145.57 Cr ₹137.6 Cr ₹131.07 Cr
Profit Before Exceptional Items & Tax ₹20.16 Cr ₹19.92 Cr ₹23.59 Cr ₹23.26 Cr ₹20.83 Cr ₹19.97 Cr ₹20.29 Cr ₹18.31 Cr ₹22.56 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹20.16 Cr ₹19.92 Cr ₹23.59 Cr ₹23.26 Cr ₹20.83 Cr ₹19.97 Cr ₹20.29 Cr ₹18.31 Cr ₹22.56 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Total Tax Expense ₹4.15 Cr ₹4.97 Cr ₹5.79 Cr ₹5.59 Cr ₹4.54 Cr ₹4.74 Cr ₹4.63 Cr ₹4.83 Cr ₹5.61 Cr ₹4.71 Cr ₹4.28 Cr ₹4.28 Cr
Net Profit ₹16.02 Cr ₹14.95 Cr ₹17.8 Cr ₹17.67 Cr ₹16.29 Cr ₹15.23 Cr ₹15.66 Cr ₹13.48 Cr ₹16.95 Cr ₹15.1 Cr ₹14.03 Cr ₹12.07 Cr
Other Comprehensive Income ₹7.7 Lakh ₹17.2 Lakh -₹17.4 Lakh ₹3.6 Lakh ₹17.5 Lakh -₹3.3 Lakh -₹22.1 Lakh -₹46.4 Lakh ₹3.6 Lakh ₹2.6 Lakh ₹2.4 Lakh -₹32.9 Lakh
Total Comprehensive Income ₹16.09 Cr ₹15.13 Cr ₹17.63 Cr ₹17.7 Cr ₹16.46 Cr ₹15.19 Cr ₹15.44 Cr ₹13.02 Cr ₹16.99 Cr ₹15.12 Cr ₹14.06 Cr ₹11.74 Cr
EBITDA (computed) ₹29.64 Cr ₹28.9 Cr ₹32.2 Cr ₹31.76 Cr ₹30.49 Cr ₹28.37 Cr ₹27.89 Cr ₹25.01 Cr ₹26.38 Cr ₹23.5 Cr ₹21.93 Cr ₹19.77 Cr
Basic EPS ₹7.60 ₹7.09 ₹8.48 ₹8.43 ₹7.77 ₹7.29 ₹7.49 ₹6.47 ₹8.15 ₹7.26 ₹6.75 ₹5.79
Diluted EPS ₹7.50 ₹7.03 ₹8.40 ₹8.34 ₹7.69 ₹7.21 ₹7.43 ₹6.44 ₹8.12 ₹7.26 ₹6.75 ₹5.79
Latest 12 quarters shown of 19 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Windlas Biotech Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Windlas Biotech Limited

As per the shareholding pattern filed with NSE for the quarter ended May 2026, promoters hold 63.31%, foreign institutional investors hold 0.99%, domestic institutional investors hold 10.20%, retail and other public shareholders hold 25.50% of Windlas Biotech Limited. The company had 46,084 shareholders on record.

Promoters: 63.31%DII (Domestic Institutional): 10.20%FII (Foreign Institutional): 0.99%Retail & Others: 25.50%
May 2026
QUARTER
63.31% Promoters
10.20% DII (Domestic Institutional)
0.99% FII (Foreign Institutional)
25.50% Retail & Others
Promoter holding - history
Now 63.31% · May 2026High 63.31% · May 2026Low 59.95% · Aug 2021
58%59.8%61.5%63.3%65%Aug 2021Sep 2022Jun 2023Sep 2024Dec 2025Aug 2021: 59.95%Sep 2021: 59.95%Dec 2021: 59.95%Mar 2022: 59.95%Jun 2022: 59.95%Sep 2022: 59.95%Dec 2022: 60.75%Feb 2023: 61.22%Mar 2023: 62.38%Apr 2023: 62.44%Jun 2023: 62.82%Sep 2023: 62.82%Dec 2023: 62.82%Mar 2024: 62.82%Jun 2024: 62.51%Sep 2024: 62.51%Dec 2024: 62.51%Mar 2025: 62.34%Jun 2025: 62.34%Sep 2025: 61.99%Dec 2025: 61.99%Mar 2026: 61.90%May 2026: 63.31%59.95%63.31%
Shareholding trend - last 6 quarters
May 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Promoters63.31%61.90%61.99%61.99%62.34%62.34%
Public36.69%38.10%38.01%38.01%37.66%37.66%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Promoters61.90%62.34%62.82%62.38%59.95%
Public38.10%37.66%37.18%37.62%40.05%
Promoter change (YoY, %pts)-0.44-0.48+0.44+2.43-

Board & Governance of Windlas Biotech Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Windlas Biotech Limited has 8 directors - 3 independent and 4 executive. The board is chaired by VIVEK DHARIWAL.

DirectorPositionOn board sinceListed boards
VIVEK DHARIWAL Non-Executive - Independent Director · Chairperson 2021-05-06 1
ASHOK KUMAR WINDLASS Executive Director 2001-02-19 1
HITESH WINDLASS Executive Director 2008-01-21 1
MANOJ KUMAR WINDLASS Executive Director 2006-04-01 1
PAWAN KUMAR SHARMA Executive Director 2019-06-11 1
GAURAV GULATI Non-Executive - Independent Director 2021-05-06 1
PRACHI JAIN WINDLASS Non-Executive - Non Independent Director 2021-05-03 1
SRINIVASAN VENKATARAMAN Non-Executive - Independent Director 2021-05-06 1
Board Committees
CommitteeMembers
Audit Committee SRINIVASAN VENKATARAMAN (Chairperson), GAURAV GULATI, HITESH WINDLASS
Nomination and remuneration committee SRINIVASAN VENKATARAMAN (Chairperson), VIVEK DHARIWAL, GAURAV GULATI
Stakeholders Relationship Committee GAURAV GULATI (Chairperson), PRACHI JAIN WINDLASS, MANOJ KUMAR WINDLASS

Charges & Borrowings of Windlas Biotech Limited

Open charges
₹73.3 Cr
Satisfied charges
₹183.4 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Limited₹40.00 Cr
Hdfc Bank Limited₹23.30 Cr
Others₹10.00 Cr
Latest charge details
DateLenderAmountStatus
27 May 2022 The Hongkong and Shanghai Banking Corporation Limited ₹40 Cr Open
04 Feb 2015 Others ₹10 Cr Open
28 Apr 2010 Hdfc Bank Limited ₹23.3 Cr Open
16 Apr 2021 Others ₹20 Cr Satisfied
16 Mar 2021 Others ₹20 Cr Satisfied

Total charge records: 29 View all charges

Employees and EPFO Compliance at Windlas Biotech Limited

Windlas Biotech Limited has a workforce of 1,153 employees as of Feb 18, 2026.

Employee count
1,153
Active EPFO establishments
1
Employee growth
8.57%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Windlas Biotech Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Windlas Biotech Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Windlas Biotech Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Windlas Biotech Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Windlas Biotech Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Windlas Biotech Limited

MSME Payment Delays by Windlas Biotech Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Windlas Biotech Limited

Subsidiaries & Group Companies of Windlas Biotech Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Windlas Biotech Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Windlas Biotech Limited

MCA Filings & Documents of Windlas Biotech Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Windlas Biotech Limited

Activity
28 Jul 2025
Windlas Biotech Limited last Annual general meeting of members was held on 28 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Windlas Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Uttarakhand.
Charges
20 Mar 2025
A charge registered on 13 Jul 2020 via Charge ID 100360093 with Sidbi was fully satisfied on 20 Mar 2025.
Charges
17 Mar 2025
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 40.00 Cr registered on 27 May 2022 with Charge ID 100575416 was modified on 17 Mar 2025.
Charges
08 Jan 2025
A charge with Hdfc Bank Limited of Rs. 23.30 Cr registered on 28 Apr 2010 with Charge ID 10223457 was modified on 08 Jan 2025.
Charges
30 Apr 2024
A charge with Others of Rs. 10.00 Cr registered on 04 Feb 2015 with Charge ID 10547318 was modified on 30 Apr 2024.

Recent News on Windlas Biotech Limited

Tano to invest in drugmaker Windlas
28 Aug 2015 · VCCircle

Frequently Asked Questions about Windlas Biotech Limited

Windlas Biotech Limited is an active public limited company in the pharma sector based in Dehradun, Uttarakhand, India. It was incorporated on 19 February 2001 (25+ years old) and is registered under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS. The company has 1,153 employees.

Windlas Biotech Limited reported revenue of ₹777.9 Cr for FY 2025 (up 21.00% YoY).

The current directors of Windlas Biotech Limited are:

The primary industry of Windlas Biotech Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Windlas Biotech Limited is listed on both BSE (code: 543329) and NSE (symbol: WINDLAS).

Windlas Biotech Limited can be reached at the registered office: 401 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110, or through the website windlas.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available